Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global inhaled nitric oxide market was valued at USD 1.07 billion in 2024. The market is projected to grow from USD 1.19 billion in 2025 to USD 2.32 billion by 2032, exhibiting a CAGR of 9.0% during the forecast period.
Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator used to treat pulmonary hypertension in newborns. It works by relaxing smooth muscle in blood vessels, improving oxygenation without affecting systemic blood pressure. The therapy was first approved by the FDA in 1999 for term and near-term neonates with hypoxic respiratory failure.
Market growth is driven by increasing prevalence of neonatal respiratory disorders, advancements in neonatal care, and expansion of indications beyond neonatal care. The market faces challenges including high treatment costs (approximately USD 3000 per treatment course) and limited accessibility in developing regions.
Mallinckrodt Pharmaceuticals dominates the market with approximately 65% market share, followed by Praxair (Linde plc), Air Liquide, and BOC Healthcare. North America accounts for 77% of the global market, followed by Europe (15%) and Asia-Pacific (8%).
Rising Prevalence of Cardiopulmonary Diseases
The increasing global incidence of pulmonary hypertension, acute respiratory distress syndrome (ARDS), and congenital heart defects is a primary driver for inhaled nitric oxide market growth. With over 1.5 million patients annually requiring pulmonary hypertension management, the demand for targeted therapies continues to grow.
Advancements in Neonatal Care
Medical communities are increasingly adopting inhaled nitric oxide as standard treatment for persistent pulmonary hypertension of the newborn (PPHN), with studies showing 65% improvement in oxygenation parameters compared to conventional therapies. The technology has become essential in level III and IV neonatal intensive care units globally.
➤ Hospitals are increasingly investing in advanced delivery systems that allow precise dosing from 1 to 80 ppm, enabling customized treatment approaches for different patient profiles
Growing healthcare expenditure in emerging economies has enabled wider adoption of advanced therapies. Countries like China, India, and Brazil are investing heavily in neonatal and pulmonary care infrastructure, creating new markets for inhaled nitric oxide products.
MARKET CHALLENGES
High Treatment Costs and Reimbursement Limitations
The average cost of inhaled nitric oxide treatment ranges from $2,500 to $4,500 per patient, creating significant financial barriers. Many healthcare systems lack comprehensive reimbursement policies, with only 43% of European countries offering full coverage. This limits adoption in middle-income countries where the disease burden is significant.
Other Challenges
Regulatory Hurdles and Approval Processes
The stringent regulatory environment for medical gases adds complexity to market entry. New suppliers face 18-24 month approval timelines even in regions with streamlined processes, creating barriers for new market entrants and limiting competitive pressure on pricing.
Limited Awareness in Developing Regions
Despite the high prevalence of pulmonary hypertension in Southeast Asia and Africa, awareness of inhaled nitric oxide therapy remains low. Medical communities in these regions often lack access to latest treatment protocols, and infrastructure challenges prevent widespread adoption of advanced delivery systems.
Expansion into Emerging Markets
Rapidly developing healthcare systems in Asia-Pacific and Latin America present significant growth opportunities. The Indian subcontinent alone represents a potential market of 2.3 million patients annually who could benefit from inhaled nitric oxide therapy. Current market penetration is less than 8%, indicating substantial room for expansion with appropriate education and infrastructure development.
Technological Innovation and Hybrid Systems
Next-generation delivery systems combining nitric oxide with other therapeutic gases (like oxygen and heliox) show promise for enhanced efficacy. Recent clinical trials demonstrate 40% better outcomes when using combination therapies. The integration of smart monitoring systems with real-time feedback loops allows for precision medicine approaches that can revolutionize treatment protocols and create new market segments.
| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Hospital Grade dominates due to its critical application in life-saving treatments and emergency medical procedures. The segment shows consistent demand from ICUs and emergency departments where precision dosing is paramount. |
| By Application |
|
Neonatal Care remains the dominant segment as inhaled nitric oxide is a standard therapy for persistent pulmonary hypertension of the newborn. The growing sophistication of neonatal ICUs globally drives consistent procedural adoption. |
| By End User |
|
Hospitals & Medical Centers lead due to their central role in critical care delivery and large patient volumes. The increasing standardization of inhaled nitric oxide protocols in ICUs creates sustained demand from major medical centers globally. |
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
Mallinckrodt Pharmaceuticals, the market leader, dominates with its INOmax® product line, capturing significant market share through established distribution networks and long-standing physician relationships. The company maintains strong market presence across North America and Europe.
Bellerophon Therapeutics follows closely with innovative delivery systems and precision dosing technologies that improve patient outcomes. Their focus on digital health integration and remote monitoring capabilities positions them as a key innovator in the market.
Third-placed Getinge AB leverages its extensive critical care portfolio to cross-sell its INO solutions. Their global presence and established infrastructure in over 40 countries enables them to serve emerging markets effectively.
Vero Biotech and Air Liquide maintain competitive positions through strategic partnerships with academic institutions and research hospitals. Their collaborative approach accelerates clinical adoption and evidence generation.
List of Key Inhaled Nitric Oxide Companies ProfiledMallinckrodt Pharmaceuticals (United States)
Bellerophon Therapeutics (United States)
Getinge AB (Sweden)
Vero Biotech Inc. (United States)
Air Liquide Healthcare (France)
Praxair Inc. (United States)
Circassia Pharmaceuticals (United Kingdom)
The global market for inhaled nitric oxide is experiencing significant growth due to increasing applications in neonatal intensive care units and pediatric cardiac surgery. Hospitals are adopting this therapy at a faster rate as clinical evidence demonstrates improved outcomes in pulmonary hypertension management. Market analysis indicates a 12.3% year-over-year growth in neonatal care applications alone.
Other TrendsExpansion into Emerging Markets
Medical infrastructure development in Asia-Pacific and Latin America is creating new growth opportunities. Countries like India, Brazil, and Indonesia are establishing specialized pediatric care centers that require advanced respiratory support systems. This expansion is driving market diversification beyond traditional North American and European markets.
Recent innovations in delivery mechanisms are improving safety and efficacy while reducing treatment costs. New generation devices offer more precise dosing control, reduced waste, and integrated monitoring systems. These advancements are particularly crucial for long-term treatment regimens and outpatient applications.
Manufacturers are responding to the demand for more portable and user-friendly systems that can be used in diverse clinical settings. The latest generation of delivery systems features improved connectivity for remote monitoring and better integration with existing hospital infrastructure.
Regulatory approvals for new indications continue to expand the potential patient population. Recent FDA approvals for use in certain pediatric heart conditions have contributed to market growth. The ongoing clinical trials for additional applications suggest this expansion will continue through the next decade.
Regional Analysis: Inhaled Nitric Oxide MarketEurope
European countries maintain strong regulatory frameworks that ensure patient safety while enabling access to advanced therapies. The EU's centralized medicines agency facilitates efficient approval processes, while individual countries maintain robust pharmacovigilance systems. Healthcare systems generally provide coverage for critically ill patients, though reimbursement rates vary. The region shows strong collaboration between academic medical centers and industry partners. Eastern European countries show increasing adoption as healthcare systems modernize, though availability remains more concentrated in Western Europe. Cross-border patient movement occasionally occurs for specialized treatments.
Asia-Pacific
The Asia-Pacific region demonstrates rapidly evolving healthcare infrastructure with particularly strong growth in Japan, South Korea, and Australia. These countries benefit from advanced medical training programs and increasing specialist availability. China and India show accelerating adoption in urban centers, though rural access remains limited. The region shows increasing clinical trial activity and growing pharmaceutical industry involvement. Medical tourism destinations increasingly market specialized respiratory care. Regulatory harmonization efforts across ASEAN countries facilitate smoother market entry, though approval timelines vary significantly across the region.
Latin America
Latin American markets show gradual but consistent growth with strongest presence in Brazil, Mexico, and Argentina. Healthcare system reforms have improved access in major cities, though rural areas remain underserved. Public health systems increasingly recognize pulmonary hypertension as priority area, though treatment availability remains concentrated in capital cities. Private healthcare providers lead in adoption of newer therapies. Economic challenges periodically affect market growth, though the region shows resilience through public-private partnership models and international health organization support.
Middle East & Africa
The Middle East shows strongest growth in Gulf Cooperation Council countries, where healthcare investment remains priority. African markets develop more gradually, with South Africa, Kenya, and Nigeria showing most progress. Specialized treatments remain concentrated in major urban centers, though telehealth initiatives improve rural access. International partnerships help build capacity through specialist training and infrastructure development. The region faces challenges in sustainable funding and infrastructure maintenance, though public-private partnerships show promise. Regional collaboration on rare disease treatment shows increasing coordination.
This market research report offers a comprehensive overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> The global inhaled nitric oxide market was valued at US$ 1.08 billion in 2024 and is projected to reach US$ 1.94 billion by 2031.
-> Key players include Mallinckrodt, Praxair (Linde plc), Air Liquide, BOC Healthcare (Linde Group), and others.
-> Key growth drivers include increasing prevalence of respiratory diseases, rising demand for targeted pulmonary therapies, and technological advancements in drug delivery systems.
-> North America is the largest market, holding about 77% of the market share, followed by Asia-Pacific and Europe.
-> Emerging trends include the development of portable nitric oxide delivery systems, integration with digital health platforms, and increased focus on personalized medicine approaches.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates